Bordetella pertussis shows polymorphism in two proteins, pertactin (Prn) and the pertussis toxin (PT) S 1 subunit, which are important for immunity. A previous study has shown antigenic shifts in these proteins in the Dutch B. pertussis population, and it was suggested that these shifts were driven by vaccination. The recent Italian clinical trial provided the opportunity to compare the frequencies of Prn and PT 51 subunit variants in strains isolated from unvaccinated children, and from children vaccinated with two acellular and one whole-cell pertussis vaccine. Four Prn variants (Prnl, Prn2, Prn3 and Prn5) were found in the 129 strains analysed. Prnl, Prn2 and Prn3 have been described previously, whereas Prn5 is a novel variant. Prnl, Prn2, Prn3 and Prn5 were found in, respectively, 6,41, 51 and 2 % of the strains. The B. pertussis strains used to produce the vaccines administered in the clinical trial were found to produce Prnl, or a type which differed from Prnl in one amino acid. The frequency of the Prnl variant was found to be lowest in the strains isolated from vaccinated groups, suggesting that Prnl strains are more affected by vaccine-induced immunity than Prn2 and Prn3 strains. Only one PT 51 type (SlA) was observed in the examined strains, which was distinct from the types produced by the vaccine strains (SlB and SlD). The S1A type also predominates in the Dutch B. pertussis population. The genetic relationship among B. pertussis strains analysed by ISl002-based DNA fingerprinting revealed that three fingerprint types predominate, representing more than 70% of the strains. Prn2 strains showed a greater variety of fingerprint types compared to Prn3, suggesting that Prn3 has emerged more recently. The results are discussed in the light of vaccine-driven evolution.
INTRODUCTION adhesion processes antigens responsible
Bordetella pertussis, the aetiological agent of whooping tussis. cough, produces many virulence factors (Leininger et al., 1990 (Leininger et al., , 1991 Relman et a[., 1989; Weiss & animal 1986) . A'nurnber of these facto filamentous haemagglutinin, fimbriae, are proteins involved rs, p&tussis toxin (PT); models showed that these antigens are efficacious in pertactin (prn) and preventing B. pertussis infections, thus supporting their in intoxication and/or use in the new generation of acellular pertussis vaccines (Cahill et al., 1993; Edwards, 1993; Kimura & KunoSakai, 1990; Peppoloni et al., 1995; Shahin et al., 1990) .
Abbreviations : Prn, pertactin; PT, pertussis toxin.
The GenBank accession number for the sequence in this paper is NO1 1016.
Recent clinical trials, successfully conducted in countries with a traditionally low rate of vaccination with the 0002-3181 0 1999SGM
whole-cell pertussis vaccine, demonstrated the high level of efficacy of some new acellular pertussis vaccines containing the above-mentioned antigens (Ad Hoc Group for the Study of Pertussis Vaccines, 1988; Greco et al., 1996; Trollfors et al., 1995; Willems & Mooi, 1996) .
T h e resurgence of pertussis experienced during recent years in countries with a long tradition in pertussis vaccination, such as the United States, the Netherlands, Canada and Australia (Andrews et al., 1997; Bass & Wittler, 1994; de Melker et al., 1997; De Serres et al., 1995) , prompted researchers to determine whether vaccination had affected the population structure of B. pertussis and had resulted in antigenic shifts (Mooi et al., 1998; van der Zee et al., 1996) . T h e results of these recent studies indicate a shift in the population structure of strains isolated in successive time periods and a divergence in the PT and Prn proteins between vaccine strains and clinical isolates. In particular, three Prn variants (Prnl, Prn2 and Prn3) and four P T S1 subunit variants (SlA, SlB, S1C and S1D) were identified. T h e variants showed differences a t the amino acid level, and the epidemiological data suggest that these changes may have been driven by vaccination (Mooi et al., 1998) .
T h e availability of strains collected during the recent Italian field trial (Greco et al., 1996; Mastrantonio et al., 1995) , in which the efficacy of a number of pertussis vaccines was evaluated, provided a unique opportunity t o compare strains isolated from vaccinated and unvaccinated children. Furthermore, it allowed us to compare strains from regions which, in the years before the beginning of the trial, presented different vaccine coverages (Cinquetti et al., 1994; Lo Palco et al., 1995) .
METHODS
Study population. Starting in 1993, 1.5601 infants at the age of 2 months were enrolled in a double-blind clinical trial to evaluate the efficacy of two new acellular pertussis vaccines.
Three pertussis vaccines combined with diphtheria and tetanus toxoids (DTP) were included : the whole-cell DTP vaccine manufactured by Connaught Lab and two acellular vaccines (DTPa), one manufactured by Chiron and the other by SmithKline Beecham Biologicals (SKB). Both the acellular vaccines contained three pertussis antigens : PT, filamentous haemagglutinin and Prn.
A fourth vaccine arm in the trial, from now on referred to as the unvaccinated group, was made up of 1555 children who received only diphtheria and tetanus toxoids. The trial study design and its results, previously published (Greco et af., 1996) , showed that each of the two acellular vaccines was 8 4 % efficacious after three doses whereas the efficacy of the whole-cell DTP vaccine was 36 "/o.
The active surveillance of the cohorts of children which received acellular vaccines is still ongoing through a mean age of 5 years, maintaining the same case definition and methods of case ascertainment (Salmaso et af., 1998 DNA sequencing of relevant regions of the prn and sl genes was performed on PCR fragments as described by Mooi et af. (1998) . Sequence analyses of prn were confined to the two regions comprising 400 bases and encoding the repeats GGxxP and PQP, designated regions 1 and 2, respectively. Region 1 was sequenced in all strains. Since no polymorphism had been previously observed in region 2, this region was sequenced in one out of five strains. Since PrnS was a new type, its gene was sequenced completely. The sequence revealed that polymorphism was restricted to region 1. The sl gene was sequenced completely. The S1 and Prn types of the Chiron and SKB vaccine strains (W 165 and Tohama, respectively) were also determined. The origin of the strain used for the Connaught whole-cell vaccine was unknown. Therefore, the S1 and Prn types were determined with the vaccine preparation used in the field trial. After amplification, the PCR products were sequenced. Appropriate negative controls were used to monitor possible contamination.
DNA fingerprinting. Strains were fingerprinted by hybridization of SmaI-digested DNA with a probe derived from ISl002, essentially as described by van der Zee et af. (1996) . Three to four external standards in each gel were used to facilitate comparison of fingerprint types between gels. After transfer to a membrane, hybridizing bands were detected with the Enhanced Chemiluminescence Gene Detection System (Amersham International). Exposed films were read with a scanner at 190 d.p.i. (HP Scanjet IIcx/T; Hewlett Packard).
Computer-assisted analysis of the IS1002 fingerprint patterns was carried out using GelCompar software (Windows N T version 4.1, Applied Maths, Kortrijk, Belgium).
Statistical analysis. P values (two-sided) were calculated with the chi-square test.
RESULTS

Polymorphism in Prn
Sequence analyses of p m were confined to the t w o regions encoding the repeats GGxxP and PQP, designated region 1 and region 2, respectively (Mooi et al., 1998) . Consistent with earlier observations only polymorphism in region 1 was found. Polymorphism in region 1 is probably generated by insertion or deletion of a repeat unit encoding the (closely related) repeats Antigenic variants in B . pertussis
BGp APA GGAVP GGAVP GGFGP GGFGP GGFGP -----VL P r n 5 GGAVP and GGFGP. Four Prn variants were found in the 129 strains analysed in this study, designated Prnl, Prn2, Prn3 and Prn5 (Fig. 1) . Prnl, Prn2 and Prn3 have been described previously (Mooi et al., 1998) Interestingly, six of the eight Prnl strains had been isolated from unvaccinated children. T h e newly described PrnS seems to be rare ( 2 % ) . Prn2 and Prn3 were equally distributed between the two acellular vaccine groups, whereas in the whole-cell vaccine group the Prn3 was predominant over Prn2 (63 versus 3 3 % ) . T h e differences between distribution of variants among the three vaccine groups and the unvaccinated group were not significant. However, when the vaccinated groups were pooled an interesting difference, although not statistically significant, in the Prnl frequency could be observed compared to the unvaccinated children (13 and 2 '/o, respectively ; P = 0.08). T h e analysis was performed on all the strains with the newly described PrnS, on most strains with Prnl, and on a similar number of Prn2 and Prn3 randomly chosen, ensuring that more than 5 0 % of strains with a specific Prn type were analysed.
Fourteen different fingerprint types were observed (Fig.  2) Indeed, in a previous study of the Dutch B. pertussis population it was found that antigenic shifts had occurred in two proteins important for immunity, Prn and PT, resulting in antigenic divergence between vaccine strains and clinical isolates (Mooi et al., 1998) .
The availability of strains collected during the recent Italian field trial (Greco et al., 1996; Mastrantonio et al., 1995) provided a unique opportunity to compare strains isolated from vaccinated and unvaccinated children, and from regions which had different vaccine coverages during the years before the beginning of the Italian trial.
In Italy, most of the children were not vaccinated against pertussis for the fear of side effects until the beginning of the double-blind clinical trial (Greco et al., 1996) and the registration of the two acellular vaccines in 1995. It is noteworthy, however, that the previous vaccination policy differed from region to region, resulting in areas with higher coverage, such as the Veneto, Piemonte and 1) l ( 1 ) 4 (5) 17 (23) 2 (3) 2 (3) 1 (1) 31 (41) 8 (11) 3 (4) 3 (4) 1 (1) l ( 1 ) l ( 1 ) 76
Friuli regions, and areas with a lower coverage, such as Puglia. However, figures for vaccination coverage in those years have been published only for Veneto and Puglia, respectively, 81 and 41 ' / o (Cinquetti et al., 1994; Lo Palco et al., 199.5) .
T h e results of this study showed the circulation of four different Prn variants, Besides the three Prn variants found in the Dutch B. pertussis population, Prnl, Prn2 and Prn3 (Mooi et al., 1998) , a novel type, Prn5, was observed. T h e Prnl variant is contained in the two acellular vaccines while the whole-cell DTP vaccine used in the field trial contained a Prn type which differed from Prnl in one amino acid. Further, it seems likely that the Prnl variant is also present in the whole-cell vaccines introduced in Italy in the 1950s and used previous to the field trial. This assumption is based on the observation that 2.5 strains, originating from a number of different countries ( i x . France, USA, UK, Japan, Finland, China and Australia) and isolated before 1960, all contained the Prnl variant (F. R. Mooi, unpublished data) . Among the Italian strains analysed, the frequency of Prnl was low compared to Prn2 and Prn3 (6, 41 and 5 1 % , respectively). T h e PrnS variant was only observed in three strains, suggesting it may have emerged recently. I t is interesting that, in contrast to Prn2 and Prn3, the frequency of Prnl was lower in the vaccinated group compared to the unvaccinated group (2 versus 13 70).
Moreover the Prnl variant was detected mainly ( i x . five out of eight Prnl strains) in Puglia, the region with a low vaccination coverage during the years before the trial. These observations suggest that strains with Prnl are more affected by vaccine-induced immunity than strains with Prn2 or Prn3 as already hypothesized in the Dutch study (Mooi et al., 1998) .
Strains with Prn3 were observed at a higher frequency in regions with a high vaccination coverage previous to the trial (Veneto and Piemonte, Prn3 frequencies 67 and 5 4 % , respectively) compared to the region with low coverage (Puglia, Prn3 frequency 3 9 % ) . In the group vaccinated with the Connaught whole-cell vaccine during the field trial, the frequency of Prn3 was nearly two times higher than the Prn2 frequency (63 and 33 ' /o, respectively). Although not statistically significant these data taken together suggest that vaccination with wholecell vaccines is less effective against Prn3 strains compared to Prn2 strains. There was no evidence for different efficacies of acellular vaccines against strains with Prn2 or Prn3, as the frequencies of these Prn types were similar in the groups vaccinated with acellular vaccines.
Four P T S1 types (SlA-D) have been described (Mooi et al., 1998) , of which only S1A was found in the Italian strains. A similar observation was made within the Dutch B. pertussis population, although S1B was also detected at a low frequency (Mooi et al., 1998) . We found that the acellular and whole-cell vaccines used during the trial contained S1B or SID. Thus, both with respect to Prn and PT, the Italian clinical isolates showed distinct variants when compared to vaccine strains. It is
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~ ~~~ ~~ important to note that, notwithstanding these differences between clinical isolates and vaccine strains, the acellular vaccines have been shown to be efficacious in the field trial (Greco et al., 1996) . Loo et al., 1999) . It is possible that these types may have spread because they are less affected by vaccine-induced immunity.
T h e distribution of the three dominant fingerprint types within the four Prn variants showed types 12 and 29 equally represented in the five analysed strains with the Prnl variant (60 and 40%, respectively) and in those with the Prn3 variant (36 and 47 70, respectively). In the Prn2 strains, type 29 predominated ( 3 7 % ) , followed by type 35 (24 ' / o ) and, at a very lower frequency, by type 12 (3 "/o). Interestingly, in the Prn2 group, a greater number of different fingerprint types was observed compared to the Prn3 strains. In fact in 35 Prn2 strains we detected 12 fingerprint types whereas in 33 Prn3 strains only five types were observed. This is consistent with the observation made on a larger sample of Prn3 strains collected in the Netherlands, and it suggests that Prn3 strains are genetically less diverse than Prn2 and may have evolved more recently (van Loo et al., 1999) . T h e populations consisting of Prn2 and Prn3 strains were significantly different with respect to the frequency of fingerprint types ( P = 0-OOZ), suggesting distinct lineages.
Thus it seems unlikely that strains switch their Prn type by insertion or deletion of repeats with a high frequency.
In conclusion, these data suggest that despite the fact that the vaccine coverage in Italy has been lower than in the Netherlands, the population structure of B. pertussis in the two countries was quite similar. This may be taken as evidence that the B. pertussis population structure was not affected by vaccination. Alternatively, the population structure may have been influenced by import from neighbouring countries with a high vaccine coverage. Finally, it is conceivable that even a relatively low vaccine coverage, like the one in Italy before the trial, has a significant effect on the bacterial population.
T h e assumption that vaccination affects the B. pertussis population structure is consistent with the observation that vaccination selects against distinct strains. For example, strains with Prnl (the vaccine type) are isolated with a lower frequency from vaccinated individuals compared to unvaccinated individuals (this study ; Mooi et al., 1998) . Further, the Prnl variant was detected mainly ( i x . five out of eight Prnl strains) in Puglia, the region with a low vaccination coverage during the years before the trial. Recently it has been shown that the presence of antibodies against Prn and P T correlate with clinical protection (Cherry et af., 1998; Storsaeter et al., 1998) . T h e circulation of variants in these antigens, which are part of most acellular vaccines, should be carefully monitored in view of their possible influence on vaccine efficacy.
